Alvotech (NASDAQ:ALVO) is acquiring Ivers-Lee Group to expand assembly and packaging capacity for biosimilar medicines. The acquisition will integrate Ivers-Lee into Alvotech’s operations, supporting growth plans and increasing flexibility to meet global demand. CEO Robert Wessman prepares for the launch of three new biosimilars in 2025.

Alvotech (NASDAQ:ALVO) is a biotechnology company specializing in biosimilar medicines with operations in Europe, North America, Asia, and Other. While ALVO shows investment potential, other AI stocks may offer greater upside and less risk. For an undervalued AI stock benefiting from tariffs and onshoring, check out the free report.

Read more at Yahoo Finance: Alvotech (ALVO) Announces Acquisition of Ivers-Lee Group